Gemcitabine, Oxaliplatin and Capecitabine for Advanced Pancreatic Carcinoma

Exclusion Criteria

• •Prior chemotherapy for pancreatic cancer
• •Prior adjuvant radio- or radiochemotherapy for pancreatic cancer within 12 months of inclusion
• •Known CNS metastases at the time of enrollment
• •Neutrophil count ≤ 1.5 x109/l, platelet count ≤100 x109/l, hemoglobin ≤ 10g/dl
• •Serum creatinine \> 1.25 x ULN
• •ASAT, ALAT and alkaline phosphatase \> 2.5 ULN or \> 5 ULN in the presence of liver metastasis, Bilirubin \> 1.5 ULN (after treatment of obstructive jaundice eg. stent)
• •Pregnant or breast feeding women (women of childbearing potential must have a negative pregnancy test at baseline)
• •Men and women of reproductive potential who are not using an effective method of contraception
• •Clinically significant cardiac disease (NYHA III-IV) or myocardial infarction within the last 12 months
• •Neurological disease with dys-/paraesthesias \> grade 1 according to NCI CTC
• •Any serious concomitant disorder incompatible with the trial (in the judgement of the investigator)
• •Psychiatric disability thought to be clinically significant in the opinion of the investigator precluding informed consent or interfering with compliance